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9 -Tetrahydrocannabinol (THC) 4 is the major psychoactive constituent of cannabis (e.g., marijuana, hashish, and hashish oil). THC is lipophilic and distributes widely throughout the body. Toxicologic analysis to determine cannabis use includes measurement of THC, the active metabolite 11-hydroxy-tetrahydrocannabinol, and the inactive metabolite 11-nor-9-carboxy-tetrahydrocannabinol. Numerous methods for the analysis of cannabinoids in blood and urine have been developed, primarily using gas chromatography-mass spectrometry (GC/MS) in electron impact ionization (EI) mode (1) (2) (3) (4) (5) (6) .
Although traditional drug testing is based on blood or urine analysis, interest in using alternative samples, such as hair, saliva, and sweat, is increasing. Advances in the sensitivity of analytical instrumentation, along with developments in sweat collection, have made possible the analysis of drugs in sweat (7) (8) (9) . One Food and Drug Administration-cleared device in current use for sweat testing is the sweat patch, marketed by PharmChem Incorporated (Haltom City, TX) under the trade name PharmChek TM . Sweat testing has been useful for monitor-ing drug use in treatment, criminal justice, and workplace drug-testing programs (10 -13 ) . Sweat patches worn for 7 days provide adequate monitoring over the entire week, thus reducing the number of visits required for effective drug monitoring. In contrast, the number of visits required to adequately monitor compliance in a drug treatment program would be three urine collections a week.
Another advantage for use of sweat as an alternative matrix is that it affords noninvasive sample collection, which is easily observed, reducing the opportunity for sample adulteration. Analytical methods for measuring amphetamines, benzodiazepines, cocaine, heroin, nicotine, and THC in sweat are available (10, (12) (13) (14) (15) (16) (17) (18) (19) (20) . Methods for measuring THC in sweat collected with PharmChek sweat patches (12 ) and by wiping the forehead with a cosmetic pad have been reported (20, 21 ) . The lowest limit of quantification (LOQ) for THC was 1.0 ng/pad or sweat patch (12, 20, 21 ) . In 16 of 198 injured drivers surveyed for drug use with the forehead wipe technique, THC concentrations ranged from 4 to 152 ng/pad (20 ) . When patches were worn for 5 days, THC was found in 9 of 20 opiate users. THC concentrations ranged from 4 to 38 ng/patch (12 ) .
Recently, the Substance Abuse and Mental Health Services Administration (SAMHSA) proposed a cutoff of 1.0 ng/patch for THC in sweat (22 ) . Analogous to SAMHSA requirements for urine drug testing, the LOQ of this assay should be 40% of the stipulated cutoff. Previous methods do not fulfill this sensitivity requirement (12, 20, 21 ) . This report describes the validation of an analytical method for the analysis of THC in human sweat patches that uses GC/MS in negative ion chemical ionization mode (GC/MS-NICI) and has adequate sensitivity for evaluating the proposed 1 ng/patch cutoff.
Given the lipophilic nature of THC, we were concerned about the possibility of THC adsorbing to the patch material. It has been acknowledged that THC adsorbs with great avidity to glass and plastic surfaces (23 ) . Additionally, THC adsorption to oral fluid collection devices has been documented (20, 24 ) . We therefore incorporated extensive stability and recovery experiments into the validation of this assay for THC from sweat patches.
Materials and Methods reagents
THC-d 0 (1 g/L in methanol) and THC-d 3 (100 mg/L in methanol) were purchased from Cerilliant. Triethylamine, ammonium chloride, and (Ϯ)-lactic acid were purchased from Sigma-Aldrich. Trifluoroacetic anhydride (TFAA) was obtained from Pierce Chemical Co. All other chemicals were reagent grade (J.T. Baker). CleanScreen columns (part no. ZSTHC020; 200 mg of sorbent, 10-mL tube volume) were used for solid-phase extraction (SPE; United Chemical Technologies). PharmChek sweat patches were supplied by PharmChem Incorporated. Artificial sweat solution was prepared to contain 327 mmol/L ammonium chloride, 166 mmol/L lactic acid, 83 mmol/L urea, 42 mmol/L acetic acid, and 34 mmol/L sodium chloride in water, and the pH was adjusted to 4.7 with 2 mol/L sodium hydroxide (25 ) .
solutions
The 1 g/L THC-d 0 solution was diluted with methanol to yield working calibrator solutions containing 16, 40, 100, 200, and 400 g/L THC-d 0 (0.4 -10 ng/patch when 25 L of each solution was added to blank worn patches). Solutions used in preparation of quality-control (QC) samples were made from a different ampoule of 1 g/L THC-d 0 than was used for preparing calibrator solutions. Working QC solutions of THC-d 0 were prepared in methanol to make QC solutions at concentrations of 24, 160, and 320 g/L (equivalent to 0.6, 4.0, and 8.0 ng/patch when 25 L was added to blank worn patches). Calibrators and QC solutions were used to evaluate inter-and intraassay accuracy and imprecision. The lowest calibrator solution was diluted in methanol to create THC-d 0 solutions that were added to blank worn patches for determining the limit of detection (LOD) and LOQ, respectively. An internal standard solution was prepared with deuterated THC (THC-d 3 ) at a concentration of 100 g/L in methanol, 10 L of which was added to each worn patch to provide an internal standard concentration of 1.0 ng/patch. All calibration solutions were stored at Ϫ20°C.
blank patches
In an attempt to mimic the sweat matrix encountered with authentic samples, we fortified blank worn sweat patches with THC to prepare calibrator and control samples. Drug-free sweat and transdermal exudate were collected from seven healthy non-cannabis-using volunteers who wore PharmChek sweat patches on the skin for at least 12 h. Before the patches were affixed, the skin area was thoroughly cleaned with a sterile 70% isopropanol swab. Worn blank patches were affixed to an index card and maintained in a freezer at Ϫ20°C until analysis. Volunteers wore multiple sweat patches at a time, and one patch from each individual's set was tested after addition of internal standard to verify undetectable THC concentrations, i.e., cannabis abstinence.
extraction procedure
Calibration, QC, and internal standard solutions were added to blank worn patches, which were placed in 6-mL glass screw-top vials. A 3.0-mL aliquot of extraction solution [methanol-0.2 mol/L sodium acetate buffer (pH 5.0), 3:1 by volume] was added. The tube was capped, vortex-mixed briefly, and placed on a reciprocal shaker at 250 rpm for 30 min. After shaking, 2.0 mL of the extracted solution was transferred to a 16 ϫ 100 mm culture tube, and 4.0 mL of 0.1 mol/L acetate buffer (pH 4.5) was added. The tubes were vortex-mixed gently, an additional 4.0 mL of 0.1 mol/L acetate buffer (pH 4.5) was added, and the tubes were centrifuged at 1300g for 5 min. SPE columns were conditioned with 3.0 mL of methanol, 3.0 mL of water, and 1.0 mL of 0.1 mol/L HCl. Diluted patch extracts were poured on the columns and allowed to drip through by gravity. Columns were washed with 2.0 mL of water and 2.0 mL of acetone-0.1 mol/L HCl (50:50 by volume), and dried under reduced pressure for at least 5 min. THC was eluted into clean screw-top centrifuge tubes by use of 3.0 mL of dichloromethane. Eluates were evaporated to dryness at 40°C under nitrogen.
derivatization Dried eluates were derivatized by adding 1.0 mL of heptane, 100 L of 0.01 mol/L triethylamine in heptane, and 20 L of TFAA. The contents in capped tubes were mixed and heated at 80°C for 20 min. After the tubes had cooled to room temperature, 0.5 mL of phosphate buffer (1.0 mol/L, pH 6.0) was added, and the tubes were vortex-mixed for 20 s before centrifugation at 1300g for 5 min. The heptane layer was transferred to a clean test tube and evaporated to dryness at 40°C under nitrogen. The residue was dissolved in 25 L of heptane and transferred to autosampler vials, from which 5.0 L was injected on the GC-MS system.
chromatographic instrumentation and analytical conditions
A Hewlett-Packard 6890 gas chromatograph with massselective detector (HP 5973) using NICI with methane (99.99% purity) as reagent gas was used for sample analysis. The injection port temperature was 250°C. Injection into the GC-MS system was performed in the pulsed splitless mode with a pulse pressure of 207 kPa (30 psi) and a pulse time of 1.5 min. A fused-silica capillary column [Rtx ® -1 capillary column; 100% dimethylpolysiloxane; 15 m ϫ 0.25 mm (i.d.); 0.25 m film thickness; Restek Corporation] was used. The GC oven was programmed with an initial temperature of 120°C, which was held for 2 min and then increased to 310°C at 30°C/min and held at the final temperature for 2 min. High-purity helium (99.999%) was used for the carrier gas at a flow rate of 1 mL/min. The temperatures of the quadrupole, ion source, and mass-selective detector interface were 100, 150, and 295°C, respectively. The MS system was operated in the selected-ion monitoring mode with the electron multiplier voltage set to 400 V relative to the daily tune value. The flow controller on the mass spectrometer was set to allow 40% methane into the mass spectrometer, with the regulator on the methane tank set to 69 kPa (10 psi). The following ions were monitored: m/z 410 for THC-d 0 , and m/z 413 for THC-d 3 .
validation experiments and acceptance criteria
Calibration by internal standardization with deuterated analogs was performed. The calibration curve was prepared by adding THC-d 0 (0.4, 1.0, 2.5, 5.0, and 10.0 ng/patch) and THC-d 3 (1.0 ng/patch) to blank worn patches. Regression analysis was performed by plotting the integrated peak-area ratios of THC-d 0 and THC-d 3 against the known added amounts of THC-d 0 . A 1/x weighting factor was applied to compensate for heteroscedasticity.
The LOD was calculated as the concentration producing a peak eluting with a relative retention time within 1% of the deuterated internal standard, having a signal-tonoise ratio of at least 3:1 and gaussian peak shape in six replicates. The LOQ was calculated as the concentration at which the LOD criteria were fulfilled and the measured concentration was within 20% of the target concentration in six replicates.
We evaluated the overall recovery of THC from blank worn sweat patches by analyzing six replicates of two sets of QC samples. Set A consisted of blank sweat patches fortified with THC-d 0 (0.6, 4.0, and 8.0 ng/patch) and 1.0 ng/patch of internal standard. Set B consisted of blank sweat patches with internal standard added to the patch, and THC-d 0 QC solution was added to the eluate after SPE. Comparison of the mean THC-d 0 integrated peak areas, (set A/set B) ϫ 100%, gave the overall THC-d 0 recovery expressed as a percentage. The mean (SD) was calculated for the six replicates.
The efficiency of the SPE of THC-d 0 was also determined. A buffer mixture was prepared with the same solutions that sweat patch extracts were dissolved in before application to SPE columns. Set A (n ϭ 6) was prepared by adding THC-d 0 QC solution (0.6, 4.0, and 8.0 ng/patch) along with 1.0 ng/patch THC-d 3 to a mixture containing 2 mL of methanol-0.2 mol/L sodium acetate buffer (pH 5.0; 3:1 by volume) and 8 mL of 0.1 mol/L acetate buffer (pH 4.5). Set B (n ϭ 6) was prepared by addition to the same solution mixture as set A with THC-d 3 added before SPE, but THC-d 0 QC solutions were added to eluates after SPE. To compute SPE efficiency, the THC-d 0 area counts for set A were divided by the counts for set B, and the difference was expressed as a percentage.
Control samples were prepared in house with THC added at 0.6, 4.0, and 8.0 ng/patch to blank worn patches and included in each batch to evaluate imprecision. The technique used to investigate imprecision was designed to simultaneously test intra-and interday imprecision. Duplicate extracted QC samples were analyzed in nine analytical runs (n ϭ 18). One-way ANOVA was performed on this dataset, using SPSS (SPSS Inc.), with day as the independent factor variable. We tested the dataset for effect of analysis date on measured concentration with a P Ͻ0.05 threshold for significance.
We examined potential interference by drugs by adding compounds commonly present in forensic or clinical samples to low-concentration QC samples (0.6 ng/patch). We tested 50 ng/patch of acetylsalicylic acid, 4-acetamidophenol, 6-acetylmorphine, amphetamine, benzoylecgonine, caffeine, cannabidiol, cannabigerol, cannabinol, Clinical Chemistry 50, No. 11, 2004 chlorpheniramine, dextromethorphan, diphenhydramine, (Ϫ)-ephedrine, ibuprofen, methadone, methamphetamine, morphine, nicotine, phencyclidine, phenylpropanolamine, and pseudoephedrine for interference with THC quantification. THC quantification within 20% of target (0.6 ng/patch) was our criterion for dismissing potential interferences.
The stability of derivatized sample extracts awaiting GC/MS analysis was investigated. To evaluate stability on the autosampler, we allowed duplicate derivatized sample extracts to sit on the autosampler at room temperature for 24 h and then analyzed them by GC/MS-NICI. The results for QC samples stored at ambient temperature for 24 h were compared with the results for QC samples analyzed within 6 h of extraction.
We also investigated the stability of stored samples, using blank worn patches fortified at the three QC concentrations. THC-d 0 was added to blank worn patches, which were stored at 4°C for 72 h, room temperature for 8 h, or freezing at Ϫ20°C and thawing at room temperature for three freeze/thaw cycles. Each condition was evaluated in triplicate. On completion of these storage cycles, THC-d 3 was added, and patches were extracted and analyzed by GC/MS-NICI.
clinical study
A healthy individual with a history of cannabis use resided in the secure clinical research unit of the Intramural Research Program, National Institute on Drug Abuse, NIH, while participating in a protocol designed to characterize the excretion of THC and metabolites in heavy chronic cannabis users. The National Institute on Drug Abuse Institutional Review Board (ethics committee) approved the study. The participant provided informed consent, was under continuous medical supervision, and was financially compensated for participation. Before admission, the participant underwent thorough medical (physical examination, electrocardiography, and blood and urine chemistries) and psychologic evaluations, including past and recent drug use history. The participant self-reported heavy, chronic cannabis use, and the measured amount in the participant's urine was Ͼ135 g/L by fluorescence polarization immunoassay (TDx; Abbott © Laboratories) on enrollment to the study. Twenty-fourhour medical surveillance and a secure ward prevented access to unauthorized licit or illicit drugs. Sweat patches were collected daily throughout the study.
Results and Discussion
This assay was conducted with GC/MS-NICI because of sensitivity requirements. NICI afforded greater sensitivity than EI. During preliminary investigations, we observed that the signal intensity of the base fragment ions differed 10-fold between GC/MS-EI and GC/MS-NICI when 5 L of unextracted THC calibrators was injected in pulsed splitless mode (data not shown). Both N,O-bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane and TFAA derivatization in EI were evaluated and provided lower sensitivity than NICI with the TFAA derivative. The limitation to using the softer ionization process, NICI, is the lack of additional fragment ions for assisting in peak identity assignment. However, the lower ionization energy of NICI selectively ionizes electronegative species, providing the molecular ion in greater abundance, improving the signal-to-noise ratio for THC. The specificity of this assay for THC was based on retention time and measurement of the molecular ion by the more selective NICI process. Sweat patches worn by seven non-cannabisusing volunteers did not contain any peaks interfering with THC-d 0 .
The GC injection port was programmed to operate in the pulsed splitless mode. Increasing the injection port pressure to 207 kPa (30 psi) vs normal splitless conditions, 26 kPa (3.9 psi), enabled reliable large-volume injection (5 L) into the GC/MS system. Operation with these pulsed splitless settings afforded a twofold increase in THC signal intensity compared with normal splitless conditions with an injection volume of 2 L.
Three sets of calibrators were used to evaluate calibration models (i.e., unweighted vs 1/x weighting). On the basis of inspection of residuals from three calibration curves, a 1/x weighting was selected for fitting the calibration curve. The weighted calibration curve was linear from 0.4 to 10 ng/patch (R 2 Ͼ0.995). The mean (SD) fitted formula of seven calibration curves yielded the formula: y ϭ 0.831(0.051)x ϩ 0.028 (0.053). All calibrators and QC samples were required to quantify within Ϯ 20% of the expected concentration for a run to be considered acceptable.
In our method, the LOD and LOQ were 0.2 and 0.4 ng/patch, respectively; when we used 2 mL of patch extraction solution (see sample chromatograms in panels A and B of Fig. 1 ). To verify our LOQ on every analytical run, we used 0.4 ng/patch as our lowest calibration point. Kintz and coworkers (12, 20 ) reported the LOD and LOQ for THC in sweat as 1.0 ng/patch, using GC-MS-EI. Thus, this method demonstrates adequate sensitivity for evaluating SAMHSA-proposed guidelines for sweat cannabinoid analysis and achieves slightly better sensitivity than previous reports.
The mean measured concentrations of our in-houseprepared controls (n ϭ 18 over 9 runs) were within 3.1% of target concentrations ( Table 1) . Results of the ANOVA did not demonstrate any significant effects of day of analysis on the low, medium, or high QC measurements (F 8,9 ϭ 2.644, 3.201, and 1.286 for low-, medium-, and high-concentration QC samples, respectively; all P Ͼ0.05). Calculated CVs for the low-, medium-, and high-concentration QC samples were Ͻ11% for interday assay imprecision ( Table 1) .
The overall recovery of THC added to dry blank sweat patches was 44.4 -45.8% for the low-, medium-, and high-concentration QC samples (Table 1) . Given the poor overall recovery of THC from sweat patches, we at-tempted to isolate whether greater loss was occurring during extraction of drug from the patch or during the SPE process. Because direct determination of recovery from the patch extraction was not feasible, we determined SPE extraction efficiency. Results of the SPE extraction efficiency study demonstrated 44.7-57.4% SPE extraction efficiency for the low-, medium-, and high-concentration QC samples, respectively (Table 1) . Thus, the greatest loss of THC during sample processing occurs during SPE.
For THC SPE, a mixture of dilute acid in organic solvent (0.1 mol/L HCl and acetonitrile, 70:30 by volume) is recommended by the vendor's application manual for washing the SPE column bed after sample application for extracting cannabinoids from blood (26 ) . Typically, an organic solvent (hexane) is the final reagent used to wash the column bed before elution of analyte. We found that THC recovery from sweat was higher when we omitted the final hexane rinse and used 0.1 mol/L HCl and acetone (50:50 by volume) as the final wash.
None of the potentially interfering drugs (50 ng/patch) altered quantification of the low-concentration QC sample by more than Ϯ 20%. Although minimal effect was observed on the quantification of the low-concentration QC sample (0.6 ng/patch) and we did not observe any interfering peaks in patches worn by seven non-cannabisusing volunteers, we advise that similar studies in which blank patches are fortified with potential interfering drugs should be conducted if this assay is to be used in a forensic or workplace setting. This would ensure that no interfering peaks are observed that could give falsepositive results.
investigation of sample storage/stability
There was more variability in area counts of both THC-d 0 and THC-d 3 after storage for 24 h at ambient temperature on the autosampler than was observed in samples 6 h after extraction. However, all samples displayed a signalto-noise ratio Ͼ3:1, and there was Ͻ5% difference of measured concentrations between samples analyzed after 6 and 24 h (Table 2) . Thus, our results demonstrate adequate THC-TFAA derivative stability at room temperature for analytical runs that proceed overnight.
Quantification of low-, medium-, and high-concentration QC samples was evaluated after storage in the refrigerator at 4°C for 72 h. The accuracy and precision for QC samples (n ϭ 6) after refrigeration for 72 h were within 15% (Table 3) . After three freeze/thaw cycles, lowand medium-concentration QC samples had acceptable quantitative values within 15% of target (Table 3) . However, after three freeze/thaw cycles, the set of highconcentration QC samples had concentrations 24% lower than the target concentration. We do not know why there appeared to be a loss of THC in the high-concentration QC samples that underwent three freeze/thaw cycles when the low-and medium-concentration QC samples quantified within 20% of the target concentrations. However, the low-and medium-concentration QC samples did quantify as 5% and 15% lower than the target concentrations, respectively.
Studies were conducted to evaluate the stability of THC added to blank patches and incubated at room temperature for 8 h. Analysis of QC solution added to dry blank worn sweat patches stored at room temperature for 8 h yielded undetectable concentrations or quantitative values Ͻ10% of the expected concentration for the highest-concentration QC sample (Table 3) . Because these THC concentrations were substantially lower than expected, we conducted similar experiments using blank worn patches moistened with 250 L of artificial sweat solution 10 min before addition of THC. The amounts of THC measured after 8 h at room temperature on moistened patches were 36 -38% of the expected THC concentrations (Table 3) . It is important to note that THC-d 3 was added to samples in these stability studies immediately before sample processing. Because THC-d 3 area counts for the study patches and calibrators were equivalent, the observed loss of THC must be related to the storage conditions. These results agree with another similar study that found Ͻ50% of expected THC concentrations during preliminary efforts to establish a proficiency testing program for sweat (John Mitchell, Research Triangle Institute, Research Triangle Park, NC, personal communication).
There are two possibilities to explain the poor recovery of added THC from sweat patches: (a) THC may bind tightly to the dry or moistened patch, making it difficult to extract; or (b) THC may be degrading while on the patch and exposed to air. We attempted to improve the yield of THC by using 3 mL of methanol instead of 3:1 methanol-acetate buffer (by volume) to improve extraction efficiency. These studies were conducted with moistened, blank worn patches that were prepared, incubated at room temperature for 8 h, and processed identically as above. The results were inconclusive; the THC yield was only marginally higher than that for extraction using 3:1 methanol-acetate buffer (by volume; Table 3 ).
Recovery of THC was improved when patches were stored at 4°C or when frozen (Table 3 ). Our analytical procedure did not attempt to monitor THC degradation products; thus, we cannot rule out this possibility as the source of poor THC recovery. However, it appears more likely that THC remains bound to the collection pad. Another important issue to consider is that constituents in human sweat may bind THC and prevent or reduce its binding to the collection pad.
There are no published data on the concentrations of THC after controlled drug administration, on the stability of THC in sweat samples, or on the extraction efficiency of THC from sweat patches. Our data suggest that THC may be poorly extracted from sweat patches because of binding of this highly lipophilic analyte to the patch material. However, adding THC dissolved in organic solvents to dry or saline-moistened sweat pads is a poor substitute for the natural processes of THC excretion in sweat. It is clear that positive THC sweat patches are routinely found when specimens collected in drug treatment and criminal justice programs across the country are tested. In these cases, sweat is collected, stored, and shipped at room temperature before analysis. Therefore, controlled THC administration studies are needed to determine the minimum detectable dose and to improve interpretation of sweat cannabinoid results. Drug testing with alternative matrices offers unique information about drug use and exposure, but it is clear that each matrix, including blood and urine, has advantages and limitations to its use as a monitoring method. A clear advantage of sweat testing is the wider window of drug detection (1 week). A disadvantage may be that collection devices, such as the PharmChek sweat patch, may adsorb some amount of drug that is difficult to recover from the device during testing. This problem also occurs with oral fluid collection devices (20, 24 ) . The tendency for THC to bind with great avidity to glass and plastic surfaces is well known, because of its high lipophilicity (23 ) . The recovery and/or stability of THC on the sweat patch may not be indicative of other, more polar drug analytes.
Doubtless THC adsorption to the collection pad reduces the sensitivity of measurement, but its practical impact is not yet known and will likely yield numerous false-negative results. The minimum amount of ingested THC that would produce a positive sweat test has not been established; therefore, we cannot judge the significance of this binding to the identification of individuals using cannabinoids. Controlled cannabinoid administration data are needed to evaluate the sensitivity of sweat testing and to improve the interpretation of cannabinoid sweat testing results.
clinical data
Sweat patches worn by a cannabis user who resided on the secure clinical research ward at the National Institute on Drug Abuse were collected after being worn for consecutive 24-h intervals after admission. These sweat patches were stored at Ϫ20°C after collection. Analysis of these patches revealed amounts of THC that were detectable by this method for 1 week after the individual began residence on the research ward, with concentrations ranging from 0.90 to 3.11 ng/patch (Table 4 and Fig. 1C) . Application of the proposed SAMHSA cutoff of 1 ng/ patch revealed that patches worn for consecutive 24-h intervals were positive up to the 5th day of cannabinoid abstinence. Because our stability studies indicate considerable loss or adherence of THC to the patch at room temperature, interpretation of cutoffs must be tempered by the understanding that the measured concentrations are not absolute for each patch but are relative to the procedure and are also influenced by storage conditions.
In conclusion, this report details the validation of a sensitive GC/MS-NICI method for measuring THC in sweat patches. The achieved LOQ was 0.4 ng/patch, and the linear range was 0.4 -10 ng/patch. Assay imprecision (CV) was Ͻ11%. Preliminary data from patches worn for consecutive 24-h periods by a cannabis user during the first days of abstinence demonstrate the usefulness of this method for measuring THC from sweat patches worn for monitoring cannabis use. In addition, this is the first report identifying the potential adsorption of THC to the sweat patch or degradation of THC on the patch that likely affects the minimum detectable dose of THC in sweat patches worn by cannabis users. These patch adsorption findings further document the need for controlled cannabis administration studies to evaluate the usefulness of sweat testing for THC.
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